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Key Points  
Npm1c and Nras-G12D co-mutation in mice leads to AML with a longer latency and a more mature 
phenotype than the Npm1c/Flt3-ITD combination 
Mutant Flt3 or Nras allele amplification is the dominant mode of progression in Npm1c/Flt3-ITD and 




NPM1 mutations define the commonest subgroup of acute myeloid leukemia (AML) and frequently 
co-occur with FLT3 internal tandem duplications (ITD) or, less commonly, NRAS or KRAS mutations. 
Co-occurrence of mutant NPM1 with FLT3-ITD carries a significantly worse prognosis than NPM1-RAS 
combinations. To understand the molecular basis of these observations we compare the effects of the 
two combinations on hematopoiesis and leukemogenesis in knock-in mice. Early effects of these 
mutations on hematopoiesis show that compound Npm1cA/+;NrasG12D/+ or Npm1cA;Flt3ITD share a 
number of features: Hox gene over-expression, enhanced self-renewal, expansion of hematopoietic 
progenitors and myeloid differentiation bias. However, Npm1cA;Flt3ITD mutants, displayed significantly 
higher peripheral leucocyte counts, early depletion of common lymphoid progenitors and a monocytic 
bias compared to the granulocytic bias in Npm1cA/+;NrasG12D/+ mutants. Underlying this was a striking 
molecular synergy manifested as a dramatically altered gene expression profile in Npm1cA;Flt3ITD, but 
not Npm1cA/+;NrasG12D/+, progenitors compared to wild type. Both double-mutant models developed 
high penetrance AML although latency was significantly longer with Npm1cA/+;NrasG12D/+. During AML 
evolution, both models acquired additional copies of the mutant Flt3 or Nras alleles, but only 
Npm1cA/+;NrasG12D/+  mice showed acquisition of other human AML mutations, including IDH1 R132Q. 
We also find, using primary Cas9-expressing AMLs, that HoxA genes and selected interactors or 
downstream targets are required for survival of both types of double-mutant AML. Our results show 
that molecular complementarity underlies the higher frequency and significantly worse prognosis 
associated with NPM1c/FLT3-ITD versus NPM1/NRAS-G12D-mutant AML and functionally confirm the 









Advances in genomics have defined the somatic mutational landscape of acute myeloid leukemia 
(AML), leading to a detailed characterisation of their prognostic significance and patterns of mutual 
co-occurrence or exclusivity. 1,2 Mutations in NPM1, the gene for Nucleophosmin, characterise the 
most common subgroup of AML representing 25-30% of all cases, result in cytoplasmic dislocation of 
the protein (NPM1c) and are mutually exclusive of leukemogenic fusion genes.1-3 As is often the case 
for fusion genes, progression to AML after the acquisition of mutant NPM1 is contingent upon the 
gain of additional somatic mutations such as those that activate STAT and/or RAS signalling3,4. For 
reasons that are not clear, this transforming step favours acquisition of internal tandem duplications 
in FLT3 (FLT3-ITD) over other somatic mutations with similar effects such as those involving NRAS or 
KRAS.1-4 Furthermore, the NPM1c/FLT3-ITD combination is associated with a significantly worse 
prognosis compared to combinations of NPM1c with mutant NRAS, KRAS or other mutations.2 
Whilst the adverse prognostic impact of NPM1/FLT3-ITD vs NPM1/RAS co-mutation influences clinical 
decisions in AML, its molecular basis and that of the frequent co-occurrence of NPM1c and FLT3-ITD 
in AML are unknown. Here, in order to investigate these phenomena, we compare the interaction of 
Npm1c with Flt3-ITD to its interaction with NrasG12D in knock-in mice. Individually, knock-in models of 
NPM1c, FLT3-ITD and NRAS-G12D display enhanced myelopoiesis and progression to 
myeloproliferative disorders or AML in a significant proportion of animals.5-7 Also, we and others have 
previously shown that Npm1c and Flt3-ITD synergise to drive rapid-onset AML8,9, but the interaction 
between Npm1c and mutant NrasG12D has not, to our knowledge, been previously investigated in 
knock-in mice10. Our findings reveal that the combination of Npm1c and Flt3-ITD has an early profound 
effect on gene expression and hematopoiesis, whilst Npm1c and Nras-G12D display only modest 
molecular synergy and subtler cellular changes. Also, whilst both types of co-mutation drove AML in 
the majority of mice, the leukemias in Npm1c;Flt3-ITD mice were more aggressive and 
undifferentiated than those which developed in Npm1c;Nras-G12D animals. At the genomic level, 
there was frequent amplification in both  models of the mutant Flt3-ITD or Nras-G12D allele, however 
additional somatic mutations in AML driver genes (e.g. Idh1 and Ptpn11) were seen only in  
Npm1c;Nras-G12D AMLs. Our findings propose that the molecular synergy between Npm1c and Flt3-




Materials and methods 
Animal husbandry 
Mx1-Cre+;Npm1flox-cA/+ were crossed with NrasLSL-G12D or Flt3ITD mice, to generate triple transgenic 
animals (Mx1-Cre;Npm1flox-cA/+;NrasLSL-G12D/+ and Mx1-Cre;Npm1flox-cA/+;Flt3ITD/+). To activate conditional 
alleles (Npm1cA and NrasG12D) in approximately 12-14 week old Mx1-Cre;Npm1flox-cA/+;NrasLSL-G12D/+ mice, 
Mx1-Cre was induced by administration of pIpC. As described previously, Mx-1 Cre;Npm1Flox-
cA/+;Flt3ITD/+ mutants do not require pIpC induction of Mx1-Cre and recombination of the Npm1flox-cA 
allele.8 For pre-leukemic analyses Npm1cA/+;NrasG12D/+ were sacrificed 4-5 weeks post pIpC and 
Npm1cA/+;Flt3ITD/+ were sacrificed at 5 weeks of age. Genotyping for mutant alleles was performed as 
previously described.5-7  
Hematological measurements 
Blood counts were performed on a VetABC analyzer (Horiba ABX). 
Histopathology 
Formalin fixed, paraffin embedded (FFPE) sections were stained with hematoxylin and eosin. Samples 
from leukemic mice were also stained with anti-CD3, anti-B220 and anti-myeloperoxidase. All material 
was examined by two experienced histopathologists (P.W. and M.A.) blinded to mouse genotypes.  
Colony-forming assays and serial re-plating 
Nucleated cells (3 x104) from bone marrow (BM) aspirates of mutant and wild-type mice were 
suspended in cytokine-containing methylcellulose-based media (M3434, Stem Cell Technologies) and 
plated in duplicate wells of 6-well plates. Colony-forming units (CFUs) were counted 7 days later. For 
serial re-plating, 3 x104 cells were re-seeded and colonies counted after 7 days. 
Flow cytometry and cell sorting 
Single cell suspensions of BM cells or splenocytes were incubated in 0.85% NH4Cl for 5 minutes to lyse 
erythrocytes. Cells were then suspended in Hank's Balanced Salt Solution (HBSS) supplemented with 
2% FCS and 10µM HEPES. Progenitor populations were defined and stained as described in 
supplementary methods. Gated cellularity was calculated by multiplying the percentage of gated cells 




Viral transduction of BM progenitors and AML cell culture. 
Lineage depleted BM aspirates, isolated from wildtype and Flt3ITD/+ mice, were transduced with MSCV-
Hoxa9-GFP and/or MSCV-Nkx2-3-CFP retroviruses and expanded for 7 days in liquid culture (X-Vivo, 
Lonza, supplemented with 10ng/ml IL-3, 10ng/ml IL-6 and 50ng/ml SCF, Peprotech). CFP, GFP or 
double positive cells were FACS sorted and 2.5 x104 cells re-plated in semi-solid media as previously 
described. BM-derived AML cells from Roas26-EF1-Cas9 mice were cultured in vitro in the presence of 
cytokines. Disruption of individual candidate genes was performed by transduction with lentivirus 
expressing gene-specific guide RNA (gRNA) and blue fluorescent protein (BFP). The impact of gene 
disruption on AML cell growth was determined using competitive co-culture of transduced (BFP+) vs 
non-transduced (BFP-) cells as described previously11 (Figure 6A, Supplemental methods).  
Microarray and comparative genomic hybridization analysis 
Mouse gene expression profiles (GEPs) were generated using the Illumina MouseWG-6 v2 Expression 
BeadChip platform (Illumina). DNA copy number variation in leukemic samples was assessed with 
Mouse Genome Comparative Genomic Hybridization 244K Microarray (acGH, Agilent Technologies). 
Full details of analysis are provided in supplemental methods. For mouse gene expression profiling, 
n=4-10 (Lin-) or n=3-5 (MPP).  
AML exome sequencing and mutation calling 
Whole exome sequencing (WES) of AML BM and control C57BL/6N or 129Sv tail DNA was performed 
using the Agilent SureSelect Mouse Exon Kit (Agilent Technologies) and paired-end sequencing on a 
HiSeq2000 sequencer (Illumina). Validation of mutations was performed using MiSeq sequencing 
(Illumina) of amplicon libraries as previously described (See Supplemental Methods Figure S1 and 
Supplemental Tables 6 and 7 for primer sequences).12,13 Full details of analysis are provided in 
supplemental methods. 
Datasets  
Microarray data were deposited at Array Express (accession number E-MTAB-5356), and RNA 
sequencing (accession numbers ERS1732539 to ERS1732546, ERS812461 and ERS812462) as well as 






Mutant Npm1 co-operates with Nras-G12D and Flt3-ITD to increase self-renewal of hematopoietic 
progenitors and expand myelopoiesis 
To understand the impact of the studied mutations, we analyzed hematopoietic cell compartments of 
Npm1cA/+;NrasG12D/+, Npm1cA/+;Flt3ITD/+, NrasG12D/+, Flt3ITD/+ and wild type (WT) mice 4-6 weeks after 
activation of conditional mutations (Figure 1). Compared to Flt3ITD/+ single mutants, Npm1cA/+;Flt3ITD/+ 
mice displayed higher white cell counts (WCC) (56±13.4 vs 6.5±0.5 x106 g/L, p<0.001) and spleen 
weights (0.63g vs 0.16g, p<0.001), but not BM cellularity (Figure 1B). By contrast, both NrasG12D/+ and 
Npm1cA/+;NrasG12D/+ mutants exhibited subtler increases in spleen weight (WT: 0.12g, NrasG12D/+: 0.18g, 
Npm1cA/+;NrasG12D/+: 0.19g, p<0.01 and p<0.001 respectively), but increased  BM cellularity  (WT: 
28.1±1.9 x106, NrasG12D/+: 43.7±2.6 x 106 and Npm1cA/+;NrasG12D/+: 41.3±3.2 x106, p<0.01 for either 
comparison vs WT) (Figure 1B). 
Expanded myelopoiesis and myeloproliferation were previously documented in single NrasG12D/+ and 
Flt3ITD/+ mutant mice.5,6 Mutant Npm1 augmented these phenotypes with increases in total Mac-1+ 
splenocytes (from 27% to 50% for NrasG12D/+; and 57% to 73% for Flt3ITD/+). Notably, these cells were 
predominantly granulocytic (Mac-1+/Gr-1+) in Npm1cA/+;NrasG12D/+ and predominantly monocytic (Mac-
1+/Gr-1-) in Npm1cA/+;Flt3ITD/+ mice (Supplemental Figure S1A).   
NrasG12D/+ mice have been shown to have increased hematopoietic stem (HSC) and progenitor cell 
numbers, due to increased proliferation and self-renewal of the HSC and multipotent progenitor 
(MPP) compartments.14,15 Our results confirm these data demonstrating significant increases in total 
myeloid progenitors i.e. granulocyte-macrophage (GMP) and common-myeloid progenitors (CMP). 
Total numbers of Sca-1/Kit positive early progenitors (LSK) and MPPs are also increased in both 
Npm1cA/+;NrasG12D/+ and NrasG12D/+ BM cells (Figure 1C and Supplemental Figure S2A). However, 
NrasG12D/+ progenitor cell composition was largely unaltered by the addition of mutant NPM1. 
Concordant with previous studies, hematopoiesis in Flt3ITD/+ mice was characterised by increased 
numbers of total myeloid progenitors (LK p<0.05 and GMPs p<0.01) and early progenitor populations 
(LSK, MPP and LMPP, p<0.01, p<0.01 and p<0.05 respectively) (Figure 1C and Supplemental Figure 
S2A). 16,17 Of note, there were detectable decreases in the size of the common lymphoid progenitor 
(CLP) population in Flt3ITD/+ and Npm1cA/+;Flt3ITD/+ mice (Figure 1C) (in part due to the reduction in Il-
7Rα-positive cells) (Figure S2B). Npm1cA/+;Flt3ITD/+ mice also exhibited robust increases in numbers of 
LK, LSK, MPP and LMPP populations, above what was observed with Flt3ITD/+, when compared to WT. 
In direct comparison with Flt3ITD/+ mutants, numbers of CMP and MEP progenitors in Npm1cA/+; Flt3ITD/+ 
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mice were reduced (from 55x103 to 16x103, p<0.05 and from 61x103 to 17x103, p<0.05), yet GMPs, 
proposed as direct descendants of CMPs18, are significantly increased. This demonstrates that Flt3ITD/+ 
mutant myelopoiesis is dramatically altered by the addition of Npm1cA/+. In direct comparison with 
Npm1cA/+;NrasG12D/+, Npm1cA/+;Flt3ITD/+  mice showed increased LMPP and  GMP populations with 
reduced numbers of lymphoid progenitors (CLP) (Figure 1E). 
In order to assess the effects on the earliest detectable hematopoietic stem cell compartment (HSC) 
we opted to perform E-SLAM staining (CD45+/EPCR+/CD48-/CD150+).19 Importantly, this does not rely 
on cell surface expression of FLT3, and reveals the percentage of E-SLAM detectable HSCs is decreased 
in Npm1cA/+;NrasG12D/+ mice and further so in Npm1cA/+;Flt3ITD/+mutants (Figure 1D). Finally, using serial 
re-plating of BM cells in semi-solid media we show that Npm1cA/+ co-mutation markedly increased self-
renewal of Flt3ITD/+ (as shown previously 8) and of NrasG12D/+ cells (Figure 1F).  
An Npm1cA/+ transcriptional signature persists in double mutant hematopoietic progenitors  
To examine their combined effects on transcription we performed comparative global gene 
expression profiling of lineage negative (Lin-) BM cells using microarrays. Npm1cA/+;NrasG12D/+ and 
Npm1cA/+;Flt3ITD/+ cells displayed a dramatically altered GEP compared to single NrasG12D/+  or Flt3ITD/+ 
mutants (Figure 2A and Supplemental Figure S3B). Previously, we showed that mouse Npm1cA/+ Lin- 
cells overexpressed several homeobox (Hox) genes (in particular overexpression of Hoxa5, Hoxa7, 
Hxa9 and two other homeobox genes, Hopx and Nkx2-3).7 Here, we show that this signature, absent 
from NrasG12D/+ or Flt3ITD/+ singular mutant mice, persists in compound Npm1cA/+;NrasG12D/+ and 
Npm1cA/+;Flt3ITD/+ Lin- progenitors. (Figure 2A, Supplemental Figure S3A-C). Gene Set Enrichment 
Analysis (GSEA) of Npm1cA/+ single and compound mutant cell GEPs, showed significant enrichment for 
genes up-regulated in NPM1-mutant and MLL-fusion gene positive human leukemias (Figure 2A).  
Overexpression of the homeobox gene NKX2.3 in human NPM1-mutant AML 
Using the human TCGA AML dataset, we compared GEPs of NPM1 mutant (NPM1c+ve) to NPM1 
wildtype (NPM1wt) AML.1 In agreement with previously published analyses, both HOXA and HOXB 
genes were significantly overexpressed in NPM1c+ve AML (Figure 2B).20 We also noted NKX2-3 was also 
overexpressed in keeping with our findings in Npm1cA/+ mice (Figure 2A). Recently, NKX2-3 
overexpression was shown to be the most effective discriminant of MLL-MLLT4 (MLL-AF6)-driven AML 
from AMLs driven by other MLL-fusion genes. 21 Whilst overexpression of Hox genes such as Hoxa9 
has been shown to impart increased self-renewal and proliferation of hematopoietic progenitors, the 
effects of Nkx2-3 overexpression are unknown. 22 To study this we performed retroviral gene transfer 
of fluorescently tagged Nkx2-3-CFP and Hoxa9-GFP into wildtype and Flt3ITD/+ Lin- cells. Cells were 
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subsequently sorted and plated in semi-solid methylcellulose for colony formation assays (Figure 2Ci). 
We find that overexpression of Nkx2-3 increases clonogenic potential, albeit to a lesser extent 
compared to Hoxa9 overexpression, in both wildtype and Flt3ITD/+ progenitors. Notably, this is not 
augmented in combined transfected cells. (Figure 2Cii).  
Hoxa gene expression is unaltered in mutant NPM1 early multipotent progenitors 
In order to mitigate the impact of the studied driver mutations on cell surface phenotypes, we 
performed transcriptome analysis on a homogeneous population of early progenitors, purified LSK- 
MPPs, (Figure 2D). Hox gene expression was not significantly altered in this population in any of the 
Npm1cA/+ models when compared to wildtype or single NrasG12D/+ and Flt3ITD/+ mutants (Figure 2E and 
Figure S3C). These results are in agreement with observations that Hox gene expression in human 
NPM1c AML blasts is comparable to that seen in WT human HSCs and myeloid progenitors.20 As we do 
not observe statistically significant expansion in total (Lin-) progenitors in single Npm1cA/+ mice (figure 
1C), these data propose that, unlike HSCs, the observed pattern of Hox overexpression in these 
progenitors is a molecular consequence of NPM1c rather than a change in cellular composition. This 
concurs with our published observations that the Hox signature is detectable even in CD19-positive B-
cells7. 
MPPs from single NrasG12D/+ or Flt3ITD/+ and the respective Npm1cA/+ compound mutant MPPs also had 
distinct transcriptional changes. Compared to WT, both NrasG12D/+ and Npm1cA/+;NrasG12D/+ MPPs 
displayed small numbers of differentially expressed genes yet only ~20% of these were shared (Figure 
2Di). GSEA did not uncover significant overlap with any pre-established expression signatures (data 
not shown). In contrast, the “addition” of Npm1cA/+ to Flt3ITD/+ in MPPs led to differential expression of 
a large number of additional genes, whilst also retaining most of the transcriptional changes 
attributable to Flt3ITD/+ (Figure 2Dii, Table S2) demonstrating the powerful synergy between Npm1cA/+ 
and Flt3ITD/+. Pathway analysis of genes differentially expressed in Npm1cA/+;Flt3ITD/+ MPPs revealed 
enrichment of genes in the JAK-STAT pathway (Supplemental Figure 3E, Supplemental Tables S4), 
including the negative regulators Cish and Socs2 (Figure 2F). A number genes, encoding proteins 
involved in MAPK signaling were also deregulated, as were genes involved in chromatin 
regulation/organisation and hematopoietic/myeloid differentiation (Figure 2F, Supplemental Figure 
3D). Many of the genes in our Npm1cA/+;Flt3ITD/+ dataset were also found deregulated in a recently 
published Tet2-/-;Flt3ITD/+ mouse model of AML (, Supplemental Figure 3F and Supplemental Table 6,) 
which serves to verify our mouse dataset technically, but also reveals a distinguishing expression 
signature of FLT3-ITD which includes Socs2, Id1, Csfr3r and Bcl11a.17 In contrast a lack of correlation 
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between deregulated gene sets of Npm1cA/+;Flt3ITD/+ and Npm1cA/+;NrasG12D/+ MPPs (Supplemental 
Figure S3D) emphasises the molecular distinction between these compound mutants.  
Npm1cA/+ and NrasG12D collaborate to promote high penetrance AML 
To understand the leukemogenic potential of combined Npm1cA/+ and NrasG12D mutations, we aged 
combined and single mutant cohorts. Compound Npm1cA/+;NrasG12D/+ and Npm1cA/+;Flt3ITD/+ mice had 
significantly reduced survival (median 138 and 52.5 days respectively) when compared to wildtype 
(618 days), Npm1cA/+ (427 days), NrasG12D/+ (315 days) and Flt3ITD/+ (also 315 days) (Figure 3A, 
Supplemental Figure S4A). No difference in the survival of NrasG12D/+ and Flt3ITD/+ mutant mice was 
observed (p=0.85, see Supplemental Figure S4A for all comparisons). At time of sacrifice, blood counts 
and tissues were collected and subjected to histopathological analysis. Aged Npm1cA/+;NrasG12D/+ and 
Npm1cA/+;Flt3ITD/+ mice exhibited characteristic AML pathological findings at a much higher frequency 
than single mutant mice. These included significantly higher WCC, reduced platelet numbers and 
substantial organ infiltration with leukemic cells (Supplemental Figure S4B-D). Histological analysis 
verified the increased AML incidence from 41% (Flt3ITD/+) to 100% in Npm1cA/+;Flt3ITD/+ samples and 
from 13% (NrasG12D/+) to 85% in Npm1cA/+;NrasG12D/+ samples (45% AML with maturation, AML+ and 
40% AML without maturation, AML- as defined by the Bethesda classification23 (Figure 3B).  
Additional somatic mutations are required for progression to AML in Npm1cA/+; NrasG12D/+ mice. 
Npm1cA/+;Flt3ITD/+ mice succumb to AML significantly more rapidly, compared to Npm1cA/+ and 
Npm1cA/+;NrasG12D/+mice. We hypothesised that the slower onset of AML in the latter two genotypes 
may be due to the requirement for additional cooperating mutations. To test this, we performed aCGH 
and WES of AMLs from Npm1cA/+, Npm1cA/+;Flt3ITD/+and Npm1cA/+;NrasG12D/+ mice. We first confirmed 
the frequent development of loss-of-heterozygosity (LOH) at the Flt3 locus in Npm1cA/+;Flt3ITD/+ AMLs 
8,24 and verified this by quantifying Flt3ITD variant allele fractions (VAFs) using PCR-MiSeq (Figure 4Ai). 
aCGH showed that LOH was copy-neutral and due to uniparental disomy of Flt3ITD (Supplementary 
Figure 4Aii). Interestingly, aCGH of Npm1cA/+;NrasG12D/+ samples revealed amplification of chr3 in 5/10 
samples tested (Figure 4Bi). This was exclusive to Npm1cA/+;NrasG12D/+ AMLs and mapped to a minimally 
amplified region (chr3: 102743581-103470550) containing Nras (Supplementary Table S10). We 
confirmed these NrasG12Dcopy gains using PCR-MiSeq and also found copy neutral LOH for NrasG12D in 
3/10 AMLs. In addition, we found copy neutral LOH in 3 of 4 Npm1cA/+;NrasG12D/+ AMLs not studied by 
aCGH. In summary, increased NrasG12D dosage was detected in 11/14 Npm1cA/+;NrasG12D/+ AMLs (Figure 




WES revealed that the average number of single nucleotide variants (SNVs) and small 
insertions/deletions (indels) per AML sample correlated positively to survival (Figure 5A). Npm1cA/+ 
AMLs spontaneously acquired mutations in genes involved in RAS signaling (Nras-p.Q61H, Cbl-
p.S374F, Ptpn11-p.S502L, Nf1-p.W1260* and Nf1-R683*) confirming this genetic interaction.  
Likewise, we detected a spontaneous tyrosine kinase domain mutation in Flt3, (Flt3-p.D842G) 
confirming the importance of FLT3 mutations in progression of NPM1-mutant AML (Figure 5B-C, 
Supplemental Table 9). Interestingly, a single Npm1cA/+;NrasG12D/+ AML harbored an Idh1-p.R132Q 
mutation and mirroring the R132H/R132C  mutations commonly seen in human AML1 whilst IDH1-
R132Q itself was reported in human chondrosarcoma.25 aCGH also revealed complete or partial gain 
of a minimally amplified region on chr7 in 7/8 Npm1cA/+ and 4/9 Npm1cA/+;NrasG12D/+ AMLs containing 
genes implicated in leukemogenesis including Nup98, Wee1 and Eed, (Supplemental Figure S5C).7,26-28 
Single copy loss of a region containing the epigenetic modifiers Wt1, Asxl1, Dnmt3a (1/8 Npm1cA/+) 
and a focal deletion of Ezh2 (1/9 Npm1cA/+; NrasG12D/+) were also detected (Figure 5C and Supplemental 
Figure S5C). 
MLL, Hox genes and their partners are required for the survival of Npm1cA-driven AML cells. 
To assess their contribution to AML maintenance in Npm1cA/+;NrasG12D/+ and Npm1cA;Flt3ITD mice, we 
employed CRISPR-Cas9 to disrupt selected deregulated genes identified by our pre-leukemic GEP, 
studies. For this, we bred with Rosa26-EF1-Cas9 animals11 to generate 
Rosa26Cas9/+;Npm1cA/+;NrasG12D/+; and Rosa26Cas9/+;Npm1cA/+;Flt3ITD/+ mice. Competitive co-culture of 
gRNA transduced and non-transduced BM cells from these mice revealed that Hoxa10 and to a lesser 
degree Hoxa9, but not Hoxa7 are required for Npm1cA/+;NrasG12D/+ and Npm1cA;Flt3ITD/+ AML 
maintenance (Figure 6B). In contrast, all three HoxA genes were required for growth of AMLs 
generated by retroviral MLL-AF9 transformation of Flt3ITD/+ BM cells (Supplementary Figure S7C).11,29,30 
Notably, although Nkx2-3 overexpression enhanced colony-forming ability of wild type and Flt3ITD/+ 
BM (Figure 2C), disruption of endogenous Nkx2-3 did not significantly affect proliferation of 
Npm1cA/+;NrasG12D/+ or Npm1cA;Flt3ITD/+ AMLs in vitro. Other genes whose disruption reduced 
proliferation of Npm1cA-driven AMLs included Mll (Kmt2a) gene, recently shown to be a therapeutic 
target in this AML type31,  Hoxa9/10 partners or co-factors including Meis1, Pbx1 and Pbx3, the HOXA9 
targets Bcl2 and Lmo232-34. A number of genes with altered expression in mutant pre-leukemic MPP 
cells, were not required for survival of AML cells in vitro (Figure 6C).  However, we cannot exclude a 
potential role for these in leukemia initiation.  
We also wanted to investigate potential differences in JAK/STAT vs RAS signaling in our AMLs in a 
similar way. FLT3-ITD leads to constitutive activation of JAK/STAT signaling, driving growth and 
transformation of hematopoietic cells35-37. In keeping with this, our transcriptome analysis revealed 
that genes involved in JAK/STAT signaling (Stat5a, Cish, Socs2) were differentially expressed in 
Npm1cA;Flt3ITD  but not in Npm1cA;NrasG12D Lin- progenitors. Nevertheless, CRISPR-targeting of Jak2 and 
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Stat5a/b genes inhibited the growth of both Npm1cA;Flt3ITD/+ and Npm1cA/+;NrasG12D/+ AML cells 
(Supplemental Figure S8B). We confirmed by RNA-seq that this was due to activation of a JAK/STAT 
programme in Npm1cA/+;NrasG12D/+ AML cells (Figure S9). In this light we conclude that the cytokines 
required for culturing primary AML cells in vitro (IL-3, IL-6 and SCF), precludes the assessment of 
signaling genes in AML growth and proliferation.  
 
Discussion 
Whilst the mutational drivers of AML and their patterns of co-occurrence are well understood, the 
molecular basis for the frequency and prognostic impact of these patterns remain unknown. Of 
particular clinical relevance are the co-occurrence patterns of mutant NPM1 mutations, which 
characterize the most common AML subtype1,2. Co-mutation of NPM1 with FLT3-ITD is both 
significantly more frequent and carries a worse prognosis than co-mutation with RAS genes.1,2 To 
understand the basis of this observation we investigated the interactions of these mutations in 
bespoke experimental models (Figure 1A).  Analysis of the short-term impact of these mutations on 
hematopoiesis confirmed that single Npm1cA/+ mutant mice have normal BM cellularity, WCC and 
splenic weight.7 As described before, single Flt3ITD/+ and NrasG12D/+ had moderate but significant 
increases in splenic size, whilst NrasG12D/+ had raised WCC and BM cellularity.5,6 Introduction of 
Npm1cA/+ into the NrasG12D/+ background did not alter these parameters significantly, yet the 
Npm1cA/+;Flt3ITD/+ co-mutation led to a dramatic rise in WCC and splenic size(Figure 1B). At the cellular 
level, the Npm1cA/+;NrasG12D/+ combination did not change progenitor and stem cell numbers when 
compared to NrasG12D/+ alone. In contrast, when compared to Flt3ITD/+ mutants, Npm1cA/+;Flt3ITD/+ mice 
displayed reductions in CMP and MEP, and increases in LSK progenitors. Furthermore, 
Npm1cA/+;Flt3ITD/+ mice showed a profound reduction in phenotypic HSCs (Figure 1 C–E).  
The differential impact of Npm1cA/+ on Flt3ITD/+ versus NrasG12D/+ was reflected in marked differences in 
GEPs between double mutant mice. The Npm1cA/+;NrasG12D/+ model displayed only minimal differences 
to single NrasG12D/+, whilst Npm1cA/+;Flt3ITD/+ lin- progenitors had profoundly different GEPs to Flt3ITD/+. 
From these and complimentary analyses of human NPM1c AML we identify NKX2-3 as a marker of this 
type of AML. Expression of NKX2-3 distinguishes MLL-AF6 and MLL-ENL from other forms of MLL-
mutant leukemia21,38, highlighting the mechanistic links between NPM1c- and MLL-fusion genes. Here, 
we show that whilst potent overexpression of Nkx2.3 by lentivirus may have an impact on self-
renewal, genetic disruption of the endogenous Nkx2.3 did not inhibit AML cell growth (Figure 6). 
We went on to age double mutant mice and report that, like Npm1cA/+;Flt3ITD/+ animals, 
Npm1cA/+;NrasG12D/+ mice also develop highly penetrant AML, albeit with a much longer latency and a 
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more mature phenotype overall. Interestingly single mutant Flt3ITD/+ and NrasG12D/+ mice had similar 
survival (Figure 3A), indicating that the interaction with Npm1cA was central to this difference. To 
understand the genetic events involved in leukemic progression, we performed exome sequencing 
and copy number analysis of Npm1cA/+;Flt3ITD/+ and Npm1cA/+;NrasG12D/+ AMLs. Interestingly, the 
commonest somatic event during AML progression was an increase in NrasG12D/+ or Flt3ITD/+ mutant 
allele burden, through copy-neutral LOH or copy number gain. In human AML, copy-neutral LOH is 
common for FLT3-ITD, but less so for mutant NRAS; for example in a recent study we identified only 
one such LOH event amongst 13 RAS mutant human AMLs.13 Nevertheless, in keeping with our 
findings, studies using the NrasG12D/+ model, in combination with retroviral insertional mutagenesis, 
resulted in high penetrance AML with frequent LOH for Nras-G12D when combined with 
overexpression of oncogenes such as Evi1.6,39 The different incidence of LOH for mutant RAS between 
murine and human AML may operate through the fact that, compared to the acquisition of other 
oncogenic mutations (e.g. Idh1-R132Q in our study), LOH for Nras-G12D may be more expedient in 
mice given the large numbers of Npm1cA/+/NrasG12D/+ pre-leukemic HSCs. Other possible reasons may 
relate to the differences in human-mouse synteny and the fact that mice are inbred potentially making 
recombination events more likely.  Notwithstanding mouse-human differences in LOH frequencies, 
our data provide strong evidence that increased mutant Flt3 and Ras gene dosage are important for 
leukemic transformation/progression. 
Finally, in order to investigate their role in Npm1c AML, we use CRISPR-Cas9 to disrupt selected genes 
in Cas9-expressing primary mouse leukemia cells. Using this approach we confirmed the requirement 
for the HoxA9/10 functional gene network in Npm1c AML maintenance. Interestingly, although it is 
widely appreciated that overexpression of Hoxa9 stimulates leukemic transformation 22,29,33, in our 
model disruption of Hoxa10 has a more detrimental impact on survival, mirroring our recent genome 
wide essentiality screen in the NPM1c-harboring OCI-AML3 cell line.11  
Our study describes the first faithful mouse model of the interaction of Npm1c with Nras-G12D, the 
preferred form of oncogenic NRAS in human AML.2 Both NPM1c models share a number of salient 
characteristics, which are imparted by mutant Npm1, such as homeobox gene overexpression and 
increased self-renewal of hemopoietic progenitors. However, we demonstrate that the co-occurrence 
of Npm1c/Flt3-ITD is significantly more leukemogenic and leads to strikingly different molecular and 
cellular consequences compared to Npm1c/Nras-G12D, providing a mechanistic explanation for the 
higher frequency and worse prognosis of NPM1c/ FLT3-ITD AML. Furthermore, through the generation 
of Cas9-expressing AML models, we also present a versatile approach for the study of genetic 
interactions in primary mouse leukemias using CRISPR. Whilst our non-Cas9-expressing Npm1c/Flt3-
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ITD model was helpful in recent studies of new anti-AML therapies31, these Cas9-expressing models 
can be utilized to study both genetic and pharmacological interactions in parallel, and also to perform 
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Figure 1. Mutant Npm1 co-operates with Nras-G12D and Flt3-ITD to enhance myeloid differentiation 
and enhance progenitor self-renewal.  
(A) Schema for Mx-1 Cre, Npm1flox-cA, NrasLSL-G12D and Flt3ITD inter-crosses. (B) NrasG12D/+ mice show a 
subtle and Npm1cA/+; Flt3ITD/+ mice a marked increase in white cell count (WCC), compared to wildtype. 
Splenic sizes were significantly increased in all mutant genotypes except Npm1cA/+, with Npm1cA/+; 
Flt3ITD/+ showing the most striking phenotype. Bone marrow cellularity was increased only in the 
presence of the NrasG12D/+ allele.  (C) FACS analysis at 4-5 weeks after mutation induction. Gating 
strategies depicted are from wildtype mice. Significant differences in the stem and progenitor cell 
compartments of NrasG12D/+ and Flt3ITD/+, but not Npm1cA/+ single mutant mice, as previously reported. 
In double mutant mice, the Npm1cA/+; NrasG12D/+ combination was not significantly different to 
NrasG12D/+, in contrast to Npm1cA/+;Flt3ITD/+ which was markedly different to both Flt3ITD/+ and Npm1cA/+ 
single mutants. (D) Using a cell surface phenotype independent of FLT3 staining, we found that 
CD45+/EPCR+/CD150+/CD48- HSCs were reduced slightly in Npm1cA/+;NrasG12D/+ and markedly in 
Npm1cA/+;Flt3ITD/+mice. (E) Summary of hematopoietic effects of Npm1cA/+;NrasG12D/+ and 
Npm1cA/+;Flt3ITD/+ double mutations in mice. LK, Lin-/Kit+; LSK, Lin-/Sca-1+/Kit+; CMP, common myeloid 
progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-monocyte progenitor; MPP, 
multi-potent progenitor; LMPP, lymphoid primed multi-potent progenitor; CLP, common lymphoid 
progenitor and HSC, hematopoietic stem cell. (F) Single Npm1cA/+ and double Npm1cA/+;NrasG12D/+ or 
Npm1cA/+;Flt3ITD/+ mutant hematopoietic progenitors show increased self-renewal potential in whole 
bone marrow serial replating assays  (n=4-8). Mean ±SEM are plotted. Significant values are reported 
for one-way analysis of variance (ANOVA, Bonferroni adjusted); (* P<0.05 vs wildtype, ** P<0.01 vs 
wildtype, *** P<0.001 vs wildtype), (∆ P<0.05 vs Flt3ITD/+, ∆∆  P<0.01 vs Flt3ITD/+, ∆∆∆  P<0.001 vs 
Flt3ITD/+), (♣ P<0.05 vs NrasG12D/+, ♣♣ P<0.01 vs NrasG12D/+, ♣♣♣ P<0.001 vs NrasG12D/+), († P<0.05 
Npm1cA/+; NrasG12D/+ vs Npm1cA/+; Flt3ITD/+, †† P<0.01 Npm1cA/+; NrasG12D/+ vs Npm1cA/+; Flt3ITD/+, ††† 
P<0.001 Npm1cA/+; NrasG12D/+ vs Npm1cA/+; Flt3ITD/+). 
Figure 2. Impact of Npm1cA/+ on the transcriptome of NrasG12D/+ and Flt3ITD/+ mutant hematopoietic 
progenitors.  
(A) Overlap of differentially expressed mRNAs reveals that Npm1cA/+ has a dramatic impact on Lin-
progenitor GEPs when combined with Flt3ITD/+, but only a modest impact when combined with 
NrasG12D/+. Nonetheless, the characteristic hallmarks of Npm1cA/+ are retained in both double mutant 
progenitors, namely overexpression of Hoxa genes and of the homeobox genes Hopx and Nkx2-3 (also 
seen in single Npm1cA/+ progenitors). Gene Set Enrichment Analysis reveals enrichment of differentially 
expressed genes from these models in human AMLs harboring mutant NPM1 or MLL gene fusions (B) 
Comparison of human NPM1-mutant (NPM1c) versus NPM1-wildtype (NPM1WT) normal karyotype 
AML (NK-AML) also shows marked overexpression of HOXA and HOXB genes, as well as of NKX2.3 
raising the possibility that the latter may mediate some of the effect of NPM1c. (C) Effects of Nkx2-3 
and Hoxa9 over-expression on mouse hematopoietic progenitors. (i) Lin- bone marrow progenitors 
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from wildtype and Flt3ITD/+ mice were transduced with MSCV-Nkx2.3-CFP and/or MSCV-Hoxa9-GFP 
constructs, maintained in liquid culture for 7 days, FACS sorted for CFP and GFP single and for double 
transfected cells and plated in semi-solid media. (ii) Colony assays of 2,500 transduced cells show that 
both  MSCV-Hoxa9 and MSCV-Nkx2-3 conferred an increase in self-renewal of both wildtype and 
Flt3ITD/+ cells. However, double MSCV-Hoxa9/MSCV-Nkx2-3 transfected cells showed no further 
changes in self-renewal when compared to MSCV-Hoxa9 alone. Mean ± SEM (n=3); *p<0.05; 
**p<0.01; ***p<0.001; students t-test). (D) Sorting strategy for LSK/CD34+/Flt3+/CD48+ progenitor 
cells and overlap of differentially expressed genes (Illumina MouseWG-6 v2 Expression BeadChip) for 
(i) NrasG12D/+ vs Npm1cA/+;NrasG12D/+ and (ii) Flt3ITD/+ vs Npm1cA/+;Flt3ITD/+ MPPs datasets. (E) Heat map of 
normalised Hox gene expression in purified (i) MPP and (ii) Lin- populations reveal that Npm1cA/+ 
mutants (single or double) have similar patterns of Hox gene expression to wildtype (normalised 
average expression values are used to generate heat map values). (F) Differentially expressed genes 
in Npm1cA/+;Flt3ITD/+ MPPs vs wildtype controls .  
Figure 3. Npm1cA and NrasG12D co-operate to drive high penetrance AML.  
(A) Kaplan Meier survival curves of wildtype (n=23), Npm1cA/+ (n=34), NrasG12D/+ (n=40), Flt3ITD/+ (n=39), 
Npm1cA/+;NrasG12D/+ (n=46) and Npm1cA/+;Flt3ITD+/ (n=40). Double mutant (Npm1cA/+;NrasG12D/+ and 
Npm1cA/+;Flt3ITD/+) mice had a significantly shortened survival when compared to single mutants, whilst 
Npm1cA/+;Flt3ITD had significantly shorter survival than Npm1cA/+;NrasG12D/+ mice. (B) Results of 
independent histopathological analysis of aged moribund mice.  Incidence of AML in compound 
Npm1cA/+;NrasG12D/+ and Npm1cA/+;Flt3ITD/+ mice is increased compared to Npm1cA/+ , NrasG12D/+ and 
Flt3ITD/+ mice. Examples of complete effacement of splenic tissue and infiltration of myeloid blast cells 
in liver tissue from Npm1cA/+; NrasG12D/+ and Npm1cA/+; Flt3ITD+/ AMLs are presented. Reduced MPO 
staining in diseased tissues is observed in samples categorized as AML without maturation (AML-) 
compared to those categorized as AML with maturation (AML+).  H&E, Haematoxylin and eosin; MPO, 
myeloperoxidase. 
Figure 4. Leukemic progression in double mutant mice involves increased NrasG12D or Flt3ITD allele 
dosage  
(A) Increase in Flt3ITD allele burden in AMLs from Npm1cA; Flt3ITD mice through loss of heterozygosity 
for the locus. (i) Flt3ITD amplicon sequencing (MiSeq) of leukemic bone marrow or spleen DNA (FN2-
FN7). Tail DNA amplified from 2-week-old Flt3+/+, Flt3ITD/+, Flt3ITD/ITD mice was used as control. (ii)  
Normalised Log2 ratio plots show copy neutrality of chr5 and the Flt3 locus in 7/7 Npm1cA; Flt3ITD 
murine AMLs (FN-AMLs) tested. (B) (i) Summary of aCGH showing copy number gain at the Nras locus 
in AMLs RN6-10. (ii) Allele fractions for Nraswt vs NrasG12D show that copy number gains in RN6-10 
involved NrasG12D, and that an additional 3 cases (RN3-5) show copy-neutral loss-of-heterozygosity. In 
addition, two more RN AMLs show gains in mutant NRAS when measuring Nraswt vs NrasG12D allele 
fractions (aCGH was not performed on these). Results of two Npm1cA/+ samples are also shown for 
comparison purposes (N6, N7). (C) Increased gene dosage of NrasG12D correlates with increased levels 
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of phosphorylated RAS effectors pERK1/2. FN2,3,4,6,7= Npm1cA;Flt3ITD AML, RN1-14= 
Npm1cA/+;NrasG12D/+ AML. 
Figure 5.  Somatic mutations in Npm1cA/+, Npm1cA/+; NrasG12D/+ and Npm1cA; Flt3ITDAMLs.  (A) Exome 
sequencing identifies an increased number of somatic nucleotide variants (SNVs) and small indels in 
Npm1cA/+, compared to Npm1cA/+; NrasG12D/+ (RN-AML) and Npm1cA; Flt3ITD (FN-AML) AML samples. 
Npm1cA/+ 6.8±0.9, Npm1cA/+; NrasG12D/+ 3.3±0.5 and Npm1cA/+; Flt3ITD/+2.6±0.7 (mean±SEM) (** p<0.01 
vs Npm1cA/+ one way ANOVA, Bonferroni adjusted). Total AMLs sequenced; Npm1cA/+ (n=12), Npm1cA/+; 
NrasG12D/+ (n=14) and Npm1cA; Flt3ITD (n=7). (B) Summary of SNVs/Indels detected in AMLs from each 
genotype as indicated. Those in blue are genes mutated in the TCGA AML dataset. Those in red are 
exact or synonymous mutations detected in the TCGA AML dataset. (C) Co-occurrence of SNVs and 
CNVs. Depicted are SNVs and focal copy number variations (CNVs) which have been formally detected 
in the TCGA AML19 dataset or detected as common insertion sites (CIS) in our previously published 
Npm1cA/+ Sleeping Beauty Transposon screen 18 . Mutant allele copy gains, chromosome gains and 
losses depicted. For copy number variation, colour coded boxes are based on log2 ratios (aCGH) and 
are not representative of CNV size. For a complete overview of all CNV and SNV co-occurrence see 
Supplemental Figure S6. 
Figure 6. MLL, Hox genes and their partners are required for the survival of Npm1cA-driven AML cells. 
(A) Schematic depicting the derivation and liquid culture of Rosa26-EF1-Cas9 expressing AML cell lines. 
CRISPR-EF1-Cas9 based assessment of individual genes aberrantly expressed in Npm1cA/+;NrasG12D/+ 
and Npm1cA;Flt3ITD mice. CAS9 activity of these mouse AML cell lines was validated as described 
previously (Supplementary Figure S7A).11 Individual Rosa26-EF1-Cas9 expressing cell lines were 
derived from two mice of each genotype. In vitro competitive assays were performed over a 23 day 
period using AML cell lines transduced with lentivirus expressing gRNAs for the indicated gene, and 
the BFP-positive fraction compared with the non-transduced population. Results were normalized to 
day 3 for each gRNA. Results from AML cell lines transduced with guide RNAs targeting Hoxa-related 
(B) and non-Hoxa related (C) genes. gRNA sequences were selected from a previously published 
library11 and are detailed in Supplementary Table S15. Guides against the pan essential Npm1 gene 
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